Psychiatry and Neurology, Neurology · Sugarland, TX
NPI
1225224157
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
16605 Southwest Freeway, Mob 3, Suite 600
Sugarland, TX, 77479
Phone (281) 274-7595
Groups this clinician bills Medicare through
Medicare paid, 2024
$114K
6,208 services
Medicare patients, 2024
394
Average age 75
Drug cost, 2024
$1.2M
3,414 prescriptions
Company payments, 2025
$3,825
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jinal Shah was code 99214 (office e&m - established), 307 times for 217 patients. In total Jinal Shah billed 6,208 services in 34 codes, and Medicare paid $114K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-04-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 307 | 217 | $81.62 | $25K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 283 | 212 | $12.46 | $3,527 |
| 95886 Electrical Nerve Conductivity | Office | 108 | 73 | $70.16 | $7,577 |
| 99215 Office E&M - Established | Office | 77 | 62 | $119.71 | $9,218 |
| 99204 Office E&M - New | Office | 50 | 50 | $103.10 | $5,155 |
| 95911 Electrical Nerve Conductivity | Office | 49 | 49 | $142.76 | $6,995 |
| 95816 Neurologic | Office | 48 | 48 | $235.83 | $11K |
| 99213 Office E&M - Established | Office | 34 | 31 | $59.23 | $2,014 |
| 95910 Electrical Nerve Conductivity | Office | 26 | 26 | $126.65 | $3,293 |
| 99483 Office/Outpatient Services | Office | 18 | 18 | $207.43 | $3,734 |
| 99205 Office E&M - New | Office | 15 | 15 | $153.15 | $2,297 |
By year: 2022 $124K for 5,202 services; 2023 $117K for 6,283 services; 2024 $114K for 6,208 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jinal Shah prescribed most often to Medicare patients was Donepezil Hcl, with 404 prescriptions and refills. In total Jinal Shah wrote 3,414 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Donepezil Hcl Generic | 404 | 894 | 110 | $3,488 |
| Memantine Hcl Generic | 370 | 644 | 77 | $13K |
| Gabapentin Generic | 330 | 567 | 97 | $4,782 |
| Pregabalin Generic | 182 | 258 | 41 | $3,236 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 154 | 318 | 37 | $2,981 |
| Quetiapine Fumarate Generic | 137 | 208 | 27 | $2,322 |
| Primidone Generic | 134 | 200 | 22 | $2,178 |
| Clonazepam Generic | 132 | 132 | 24 | $699 |
| Duloxetine Hcl Generic | 113 | 195 | 28 | $2,116 |
| Levetiracetam Generic | 99 | 207 | 24 | $2,692 |
| Escitalopram Oxalate Generic | 88 | 113 | 18 | $816 |
| Topiramate Generic | 71 | 115 | 15 | $654 |
| Prednisone Generic | 64 | 74 | Under 11 | $423 |
| Ropinirole Hcl Generic | 59 | 138 | 15 | $720 |
| Pyridostigmine Bromide Generic | 54 | 84 | Under 11 | $2,900 |
Brand drugs: 246 claims; generic drugs: 3,168 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jinal Shah $3,825 ($3,825 in general payments such as food, travel and fees) from 29 companies. The largest payer was Abbvie Inc. with $746.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 43 | $746 |
| Pfizer Inc. PFE | 28 | $387 |
| UCB, Inc. UCB.BR | 19 | $380 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $219 |
| Argenx US, Inc. ARGX | 7 | $198 |
| Alexion Pharmaceuticals, Inc. AZN | 8 | $180 |
| EMD Serono, Inc. MRK.DE | 8 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $150 |
| Neurocrine BioSciences, Inc. NBIX | 6 | $143 |
| Biogen, Inc. BIIB | 6 | $129 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.